A face‐to‐face comparison of the BBB cell models hCMEC/D3 and hBMEC for their applicability to adenoviral expression of transporters
Open Access
- 12 May 2024
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (9) , 2611-2620
Abstract
The blood–brain barrier (BBB) is a structure mainly formed by brain capillary endothelial cells (BCEC) whose role is to regulate the exchange of compounds between the blood and the brain. In this process efflux and uptake transporters play a key role. Aim of this study was to compare the two previously established cell lines hCMEC/D3 and hBMEC as BBB cell models for the application of an adenoviral system to transiently express OATP2B1 and Pgp. Comparison of hCMEC/D3 and hBMEC mRNA and protein levels of BBB markers showed a unique expression pattern for each cell line. While showing similar expression of the efflux transporter BCRP, transferrin receptor (TFRC) and of the tight junctions proteins Occludin and ZO‐1, hCMEC/D3 displayed higher levels of the endothelial marker PECAM1, VE‐cadherin, Von Willebrand Factor (VWF) and of the efflux transporter Pgp. Moreover, measuring integrity of the monolayer by determining the Trans‐Endothelial Electrical Resistance (TEER), electrical capacitance (CCl), and inulin apparent permeability coefficient (Papp) revealed higher TEER and lower CCl for hBMEC but comparable Papp in the two cell lines. Following adenoviral infection, enhanced OATP2B1 and Pgp expression and functionality could be observed only in hBMEC. Importantly, the adenoviral expression system did not affect expression of BBB markers and permeability in both cell lines. Taken together, our results provide first evidence that hBMEC is an applicable human BBB cell model in which adenoviral infection can be used to transiently express and investigate transporters of interest. imageKeywords
This publication has 24 references indexed in Scilit:
- Re-evaluation of the hCMEC/D3 based in vitro BBB model for ABC transporter studiesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2022
- Proteomic Quantification of Human Blood–Brain Barrier SLC and ABC Transporters in Healthy Individuals and Dementia PatientsMolecular Pharmaceutics, 2019
- Establishment and Validation of Competitive Counterflow as a Method To Detect Substrates of the Organic Anion Transporting Polypeptide 2B1Molecular Pharmaceutics, 2018
- Quantitative Atlas of Blood–Brain Barrier Transporters, Receptors, and Tight Junction Proteins in Rats and Common MarmosetJournal of Pharmaceutical Sciences, 2013
- Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug InteractionsJournal of Medicinal Chemistry, 2012
- In Vitro Blood–Brain Barrier Models: Current and Perspective TechnologiesJournal of Pharmaceutical Sciences, 2012
- Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heartClinical Pharmacology & Therapeutics, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Bacterial invasion and transcytosis in transfected human brain microvascular endothelial cellsMicrobial Pathogenesis, 2001
- The P-Glycoprotein Efflux Pump: How Does it Transport Drugs?The Journal of Membrane Biology, 1997